Fortunato Iacovelli

Dr. Fortunato Iacovelli

Institute of Cardiovascular Disease, Department of Emergency and Organ Transplantations, University of Bari “Aldo Moro”, 70124 Bari, Italy
orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2017 in EuroIntervention
Verified
Journal Article
Closed access
ACAngelo Cioppa
Angelo Cioppa
ESEugenio Stabile
Eugenio Stabile
LSLuigi Salemme
Luigi Salemme
GPGrigore Popusoi
Grigore Popusoi
APArmando Pucciarelli
Armando Pucciarelli
TTTullio Tesorio
Tullio Tesorio
The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

1 December 2022 in Circulation: Cardiovascular Interventions
Verified
Journal Article
Closed access
PDF file
GCGiuliano Costa
Giuliano Costa
TPThomas Pilgrim
Thomas Pilgrim
ISIgnacio J. Amat Santos
Ignacio J. Amat Santos
OBOle De Backer
Ole De Backer
WKWon-Keun Kim
Won-Keun Kim
FRFor The Revasc-Tavi Registry
For The Revasc-Tavi Registry
Background: The best management of stable coronary artery disease (CAD) in patients undergoing transcatheter aortic valve implantation (TAVI) is still unclear due to the marked inconsistency of the available evidence. Methods: The REVASC-TAVI registry (Management of Myocardial Revascularization in Patients Undergoing Transcatheter Aortic Valve Implantation With Coronary Artery Disease) collected data from 30 centers worldwide on patients undergoing TAVI who had significant, stable CAD at preprocedural work-up. For the purposes of this analysis, patients with either complete or incomplete myocardial revascularization were compared in a propensity score matched analysis, to take into account of baseline confounders. The primary and co-primary outcomes were all-cause death and the composite of all-cause death, stroke, myocardial infarction, and rehospitalization for heart failure, respectively, at 2 years. Results: Among 2407 patients enrolled, 675 pairs of patients achieving complete or incomplete myocardial revascularization were matched. The primary (21.6% versus 18.2%, hazard ratio‚ 0.88 [95% CI, 0.66–1.18]; P =0.38) and co-primary composite (29.0% versus 27.1%, hazard ratio‚ 0.97 [95% CI, 0.76–1.24]; P =0.83) outcome did not differ between patients achieving complete or incomplete myocardial revascularization, respectively. These results were consistent across different prespecified subgroups of patients (< or >75 years of age, Society of Thoracic Surgeons score > or or 0.10). Conclusions: The present analysis of the REVASC-TAVI registry showed that, among TAVI patients with significant stable CAD found during the TAVI work-up, completeness of myocardial revascularization achieved either staged or concomitantly with TAVI was similar to a strategy of incomplete revascularization in reducing the risk of all cause death, as well as the risk of death, stroke, myocardial infarction, and rehospitalization for heart failure at 2 years, regardless of the clinical and anatomical situations.

30 January 2023 in JACC
Verified
Journal Article
Closed access
ASAlessandro Spirito
Alessandro Spirito
LVLukas Vaisnora
Lukas Vaisnora
APAthanasios Papadis
Athanasios Papadis
FIFortunato Iacovelli
Fortunato Iacovelli
CSCelestino Sardu
Celestino Sardu
LRLorenz Räber
Lorenz Räber

10 October 2017 in BMC Cardiovascular Disorders
Verified
Journal Article
Open access
PDF file
MBMarco Barbanti
Marco Barbanti
JBJan Baan
Jan Baan
MSMark S. Spence
Mark S. Spence
FIFortunato Iacovelli
Fortunato Iacovelli
GMGian Luca Martinelli
Gian Luca Martinelli
CTCorrado Tamburino
Corrado Tamburino
There is an increasing trend towards shorter hospital stays after transcatheter aortic valve implantation (TAVI), in particular for patients undergoing the procedure via transfemoral (TF) access. Preliminary data suggest that there exists a population of patients that can be discharged safely very early after TF-TAVI. However, current evidence is limited to few retrospective studies, encompassing relatively small sample sizes. The Feasibility And Safety of early discharge after Transfemoral TAVI (FAST-TAVI) registry is a prospective observational registry that will be conducted at 10 sites across Italy, the Netherlands and the UK. Patients will be included if they have been scheduled to undergo TF-TAVI with the balloon-expandable SAPIEN 3 transcatheter heart valve (THV; Edwards Lifesciences, Irvine, CA). The primary endpoint is a composite of all-cause mortality, vascular-access-related complications, permanent pacemaker implantation, stroke, re-hospitalisation due to cardiac reasons, kidney failure and major bleeding, occurring during the first 30 days after hospital discharge. Patients will be stratified according to whether they were high or low risk for early discharge (≤3 days) (following pre-specified criteria), and according to whether or not they were discharged early. Secondary endpoints will include time-to-event (Kaplan–Meier) analysis for the primary outcome and its individual components, analysis of the relative costs of early and late discharge, and changes in short- and long-term quality of life. Multivariate logistic regression will be used to identify factors that indicate that a patient may be suitable for early discharge. The data gathered in the FAST-TAVI registry should help to clarify the safety of early discharge after TF-TAVI and to identify patient and procedural characteristics that make early discharge from hospital a safe and cost-effective strategy. ClinicalTrials.gov Identifier: NCT02404467 (registration first received March 23rd 2015).

26 December 2022 in Hellenic Journal of Cardiology
Verified
Journal Article
Open access
FLFrancesco Loizzi
Francesco Loizzi
OBOsvaldo Burattini
Osvaldo Burattini
ACAlessandro Cafaro
Alessandro Cafaro
FSFrancesco Spione
Francesco Spione
LSLuigi Salemme
Luigi Salemme
FIFortunato Iacovelli
Fortunato Iacovelli
Acute kidney injury (AKI) after transcatheter aortic valve implantation (TAVI) is a frequent complication associated with adverse outcomes and mortality. Various scores have been developed to predict this complication in the coronary setting. However, none have ever been tested in a large TAVI population. This study aimed to evaluate the power of four different scores in predicting AKI after TAVI. Overall, 1535 consecutive TAVI patients from the observational multicentric "Magna Graecia" TAVI registry were included in the analysis. Of the study population, 235 (15.31%) developed AKI early. The Mehran, William Beaumont Hospital, CR4EATME3AD3, and ACEF scores were calculated retrospectively. The patients who developed TAVI-related AKI had significantly higher absolute values of all risk scores than those who did not. The receiver-operating characteristic analysis also showed a significant correlation between these four scores and AKI, but without a significant difference among all of them (p value = 0.176). Nevertheless, based on their area under the curve values (≤0.604 for all), none had adequate diagnostic accuracy in predicting TAVI-related AKI. Importantly, multivariate analysis identified myocardial revascularization close to the TAVI procedure and implantation of self-expanding prostheses, as well as atrial fibrillation, low-osmolar contrast media administration, corrected contrast medium volume, and any transfusion (p value < 0.05 for all) as independent risk factors for AKI. Although high values of current AKI risk scores are significantly associated with the development of this complication, these are not sufficiently accurate. Further studies are needed so that a TAVI-dedicated AKI risk score may be created.

30 August 2019 in Journal of Thrombosis and Thrombolysis
Verified
Journal Article
Closed access
PDF file
DADonatella Argentiero
Donatella Argentiero
SSStefano Savonitto
Stefano Savonitto
PDPaola D’aNdrea
Paola D’aNdrea
FIFortunato Iacovelli
Fortunato Iacovelli